Evidence map›Paper›PMID 26732427›Full record

SynthesisHuman molecular genetics2016

Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry.

Jonine D Figueroa, Candace D Middlebrooks, A Rouf Banday, Yuanqing Ye, Montserrat Garcia-Closas, Nilanjan Chatterjee, Stella Koutros, Lambertus A Kiemeney, Thorunn Rafnar, Timothy Bishop and 117 more

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human molecular genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Rare Variant rs35356162 inFrontiers in oncology · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

127 authors at 20 institutions in 15 countries.

Jonine D FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Usher Institute of Population Health Sciences and Informatics, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK, jonine.figueroa@ed.ac.uk.
Candace D MiddlebrooksDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
A Rouf BandayDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Yuanqing YeDepartment of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA.
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Nilanjan ChatterjeeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Stella KoutrosDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Lambertus A KiemeneyRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Thorunn RafnardeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Timothy BishopSection of Epidemiology and Biostatistics.
Helena FurbergDepartment of Epidemiology and Biostatistics.
Giuseppe MatulloDepartment of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy.
Klaus GolkaLeibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
Manuela Gago-DominguezGenomic Medicine Group, Galician Foundation of Genomic Medicine, Servicio Galego de Saude (SERGAS), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
Jack A TaylorEpidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC, USA.
Tony FletcherLondon School of Hygiene and Tropical Medicine, London, UK.
Afshan SiddiqSchool of Public Health.
Victoria K CortessisDepartment of Preventive Medicine, USC Keck School of Medicine, Department of Obstetrics and Gynecology, Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Charles KooperbergDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Olivier CussenotDepartment of Urology, Tenon, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France.
Simone BenhamouInstitut national de la sante et de la recherche medicale, U946, Foundation Jean Dausset Centre d'Etude du Polymorphisme Humain (CEPH), Paris, France, Centre National de la Receherche Scientifique, UMR8200, Institut Gustave-Roussy, Villejuif, France.
Jennifer PrescottChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology.
Stefano PorruDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Colin P DinneyDepartment of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Núria MalatsGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Dalsu BarisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Eric J JacobsEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Zhaoming WangCancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, USA.
Charles C ChungDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Sita H VermeulenRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Katja K AbenRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Tessel E GaleslootRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Gudmar ThorleifssondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Patrick SulemdeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Kari StefanssondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Anne E KiltieCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.
Mark HarlandSection of Epidemiology and Biostatistics.
Mark TeoRadiotherapy Research Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK.
Kenneth OffitDepartment of Medicine.
Joseph VijaiDepartment of Medicine.
Dean BajorinGenitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine.
Ryan KoppUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Giovanni FioritoDepartment of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy.
Simonetta GuarreraDepartment of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy.
Carlotta SacerdoteCancer Epidemiology, CPO Piemonte, Turin, Italy.
Silvia SelinskiLeibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
Jan G HengstlerLeibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
Holger GerullisUniversity Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany, Department of Urology, Lukasklinik Neuss, Germany.
Daniel OvsiannikovDepartment of Urology, St. Josefs Hospital, Dortmund-Hörde, Germany.
Meinolf BlaszkewiczLeibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
Jose Esteban CastelaoOncology and Genetics Unit, Complejo Hospitalario, Instituto de Investigacion Biomedica (IBI) Orense-Pontevedra-Vigo, Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
Manuel CalazaGenomic Medicine Group, Galician Foundation of Genomic Medicine, Servicio Galego de Saude (SERGAS), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Galicia, Spain.
Maria Elena MartinezDepartment of Family Medicine and Public Health, Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Patricia CordeiroDepartment of Urology, Complejo Hospitalario, University of Santiago de Compostela, Servicio Galego de Saude (SERGAS), Santiago de Compostela, Spain.
Zongli XuEpidemiology Branch, National Institute of Environmental Health Sciences (NIEHS).
Vijayalakshmi PanduriEpidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC, USA.
Rajiv KumarDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eugene GurzauEnvironmental Health Center, Cluj, Romania.
Kvetoslava KoppovaState Health Institute, Banska Bystrica, Slovakia.
H Bas Bueno-De-MesquitaSchool of Public Health, Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Börje LjungbergDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden.
Françoise Clavel-ChapelonInserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women's Health team, Villejuif F-94805, France, Université Paris Sud, UMRS 1018, Villejuif F-94805, France, Institut Gustave Roussy, Villejuif F-94805, France.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway, Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland.
Vittorio KroghEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Miren DorronsoroHealth Department, BioDonostia Research Institute, Basque Region, Spain, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Ruth C TravisCancer Epidemiology Unit, University of Oxford, Oxford, UK.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Paul BrennanInternational Agency for Research on Cancer (IARC), Lyon, France.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Elio RiboliSchool of Public Health.
David ContiSchool of Public Health, Department of Obstetrics and Gynecology.
Marianna C SternSchool of Public Health, Department of Obstetrics and Gynecology.
Malcolm C PikeSection of Epidemiology and Biostatistics.
David Van Den BergSchool of Public Health, Department of Obstetrics and Gynecology.
Jian-Min YuanUniversity of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Chancellor HohenseeDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Rebecca P JeppsonDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Geraldine Cancel-TassinCentre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France.
Morgan RoupretDepartment of Urology, Pitié-Salpétrière, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France.
Eva ComperatDepartment of Pathology, Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris (APHP), Paris, France, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France.
Constance TurmanDepartment of Epidemiology.
Immaculata De VivoNorris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Edward GiovannucciChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology, Department of Nutrition.
David J HunterChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology, Department of Nutrition, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Peter KraftDepartment of Epidemiology, Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA.
Sara LindstromDepartment of Epidemiology.
Angela CartaDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Sofia PavanelloDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Cecilia AriciDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Giuseppe MastrangeloDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Ashish M KamatDepartment of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Liren ZhangDepartment of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA.
Yilei GongDepartment of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA.
Xia PuDepartment of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA.
Amy HutchinsonCancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, USA.
Laurie BurdettCancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, USA.
William A WheelerInformation Management Services, Silver Spring, MD, USA.
Margaret R KaragasGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Alison JohnsonVermont Cancer Registry, Burlington, VT, USA.
Alan SchnedGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
G M Monawar HosainNew Hampshire State Cancer Registry, Concord, NH, USA.
Molly SchwennMaine Cancer Registry, Augusta, ME, USA.
Manolis KogevinasCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Municipal Institute of Medical Research, (IMIM-Hospital del Mar), Barcelona, Spain, National School of Public Health, Athens, Greece.
Adonina TardónCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.
Consol SerraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Municipal Institute of Medical Research, (IMIM-Hospital del Mar), Barcelona, Spain, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Alfredo CarratoRamon y Cajal University Hospital, IRYCIS, Madrid, Spain.
Reina García-ClosasUnidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain.
Josep LloretaCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Gerald AndrioleDivision of Urologic Surgery, Washington University School of Medicine, Saint Louis, MO, USA and.
Robert GrubbDivision of Urologic Surgery, Washington University School of Medicine, Saint Louis, MO, USA and.
Amanda BlackDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
W Ryan DiverEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Stephanie WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jarmo VirtamoDepartment of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland.
Christopher A HaimanDepartment of Obstetrics and Gynecology.
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Joseph F FraumeniDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Paolo VineisHuman Genetics Foundation, Turin, Italy, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.
Xifeng WuDepartment of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Debra T SilvermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Ludmila Prokunina-OlssonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Division of Cancer Epidemiology and GeneticsNational Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESFaculty of Public Health · GBCancer Research And Biostatistics · USdeCODE Genetics (Iceland) · ISAmerican Cancer Society · USBrigham and Women's Hospital · USFred Hutch Cancer Center · USRadboud University Nijmegen · NLUniversity of Brescia · ITDartmouth College · USHarvard University · USInstituto de Investigación Sanitaria de Santiago · ESLeibniz Research Centre for Working Environment and Human Factors · DEOnco-Urologie PrédictiveTU Dortmund University · DEUniversity of Padua · ITUniversity of Turin · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
JH/CIDR Genotyping for Genome-Wide Association StudiesU01HG004438 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2007 to 2011
$24.2M
Genetic Epidemiology of CancerZIAHG200331 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BAILEY-WILSON, JOAN ELLEN · 2009 to 2022
$11.7M
NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
Genetic Susceptibility And The Environment In Cancer RiskZIAES049033 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI TAYLOR, JACK A · 2009 to 2022
$7.7M
Cancer Genetic Markers of SusceptibilityZIACP010187 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CHANOCK, STEPHEN J. · 2009 to 2025
$4.7M
Cancer Research UK 10589Cancer Research UK 12933Cancer Research UK 16491Cancer Research UK 19167NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NCI NIH HHS R01 CA057494NCI NIH HHS U01 CA164973NHGRI NIH HHS U01 HG004438World Health Organization 001
6 · The paper itself

Abstract

Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up on four promising single-nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance in 6911 cases and 11 814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P < 1 × 10(-6)), using additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS data. In a combined analysis, which included data on up to 15 058 cases and 286 270 controls, two SNPs achieved genome-wide statistical significance: rs6104690 in a gene desert at 20p12.2 (P = 2.19 × 10(-11)) and rs4907479 within the MCF2L gene at 13q34 (P = 3.3 × 10(-10)). Imputation and fine-mapping analyses were performed in these two regions for a subset of 5551 bladder cancer cases and 10 242 controls. Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two signals in the 20p12.2 region-the first signal is marked by rs6104690, and the second signal is marked by two moderately correlated SNPs (r(2) = 0.53), rs6108803 and the previously reported rs62185668. The second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-case P ≤ 0.02 for both rs62185668 and rs6108803). Functional analyses are needed to explore the biological mechanisms underlying these novel genetic associations with risk for bladder cancer.

Indexed as

Chromosomes, Human, Pair 13Chromosomes, Human, Pair 20Biomarkers, TumorCase-Control StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLinkage DisequilibriumMalePolymorphism, Single NucleotideRisk FactorsUrinary Bladder NeoplasmsWhite PeopleBiomarkers, Tumor

Identifiers

PMID26732427
PMCPMC4817084
OpenAlexW2225833867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.